PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17289040-5 2007 INTERVENTION(S): Administration of diazoxide to lower circulating insulin concentrations. Diazoxide 35-44 insulin Homo sapiens 66-73 17587399-2 2007 The aim of the present study was to investigate the effect of inhibition of insulin secretion by diazoxide on weight loss in obese, normoglycaemic (fasting plasma glucose of > or =6.1 mmol/l), hyperinsulinaemic (fasting plasma insulin of > or =100 pmol/l) adults during a 2.5 MJ/day energy-deficient diet. Diazoxide 97-106 insulin Homo sapiens 76-83 17587399-8 2007 Eight weeks of diazoxide decreased incremental area under the response curve (iAUC) for insulin (iAUC(insulin)) and for C-peptide (iAUC(C-peptide)) and increased iAUC for glucose (iAUC(glucose)) during the OGTT and the test meal compared with the use of placebo (p < 0.003). Diazoxide 15-24 insulin Homo sapiens 88-110 17587399-8 2007 Eight weeks of diazoxide decreased incremental area under the response curve (iAUC) for insulin (iAUC(insulin)) and for C-peptide (iAUC(C-peptide)) and increased iAUC for glucose (iAUC(glucose)) during the OGTT and the test meal compared with the use of placebo (p < 0.003). Diazoxide 15-24 insulin Homo sapiens 120-129 17587399-8 2007 Eight weeks of diazoxide decreased incremental area under the response curve (iAUC) for insulin (iAUC(insulin)) and for C-peptide (iAUC(C-peptide)) and increased iAUC for glucose (iAUC(glucose)) during the OGTT and the test meal compared with the use of placebo (p < 0.003). Diazoxide 15-24 insulin Homo sapiens 136-145 17559844-2 2007 DESIGN: Transversal assessment at baseline and prospective follow-up of lean PCOS group after 8 days of diazoxide, which reduces insulin secretion, and 1 month of leuprolide, which suppresses LH. Diazoxide 104-113 insulin Homo sapiens 129-136 17360975-11 2007 Finally, the ATP-sensitive K(+) channel agonist diazoxide (200 micromol/l) inhibited GKA50-induced insulin release and its elevation of [Ca(2+)](i.) Diazoxide 48-57 insulin Homo sapiens 99-106 17296510-8 2006 Diazoxide, used efficiently in certain cases of HI, opens the K(ATP) channels and therefore overpass the mutation effect on the insulin secretion. Diazoxide 0-9 insulin Homo sapiens 128-135 16475928-5 2006 Openers of Kir6.2/SUR1 channels, e.g. diazoxide, have in contrast only found limited clinical use in treatment of hypersecretion of insulin associated with certain tumours (insulinoma) and genetic disorders (persistent hyperinsulinemia and hypoglycemia of infancy, PHHI). Diazoxide 38-47 insulin Homo sapiens 132-139 16527842-4 2006 DPH also suppressed insulin release in the presence of 16.7 mm glucose, 200 microm diazoxide, and 30 mm K+ without affecting the intracellular Ca2+ concentration. Diazoxide 83-92 insulin Homo sapiens 20-27 15339745-2 2005 Intravenous diazoxide produced rapid, but transient, decrements (P = 0.0023) in plasma insulin (e.g., nadirs of 2.8 +/- 0.5 and 1.8 +/- 0.3 microU/ml compared with 7.0 +/- 1.0 microU/ml after saline at 4.0-7.5 min) and C-peptide (P = 0.0228) associated with dose-related increments in plasma glucose (P = 0.0044) and serum nonesterified fatty acids (P < 0.0001). Diazoxide 12-21 insulin Homo sapiens 87-94 15339745-8 2005 These findings define the temporal patterns and magnitudes of the metabolic responses to diazoxide and underscore the primacy of regulated insulin secretion in the physiological regulation of postabsorptive carbohydrate and lipid metabolism. Diazoxide 89-98 insulin Homo sapiens 139-146 15811140-0 2005 Diazoxide-mediated insulin suppression in obese men: a dose-response study. Diazoxide 0-9 insulin Homo sapiens 19-26 15811140-1 2005 BACKGROUND: It has been suggested that diazoxide (DZX)-mediated insulin suppression may be useful to promote weight loss in obese subjects. Diazoxide 39-48 insulin Homo sapiens 64-71 15811140-1 2005 BACKGROUND: It has been suggested that diazoxide (DZX)-mediated insulin suppression may be useful to promote weight loss in obese subjects. Diazoxide 50-53 insulin Homo sapiens 64-71 15811140-3 2005 METHODS: Assessment of DZX efficacy and safety was based on plasma glucose and insulin responses to a standardized 500-kcal breakfast, taken on the sixth day of treatment. Diazoxide 23-26 insulin Homo sapiens 79-86 15811140-6 2005 RESULTS: In non-obese subjects, DZX 50 mg decreased peak insulin levels by +/-28% and raised peak glucose concentration from 7.1 +/- 0.6 to 7.8 +/- 0.6 mmol/l (p < 0.05). Diazoxide 32-35 insulin Homo sapiens 57-64 15811140-7 2005 DZX 100 mg reduced peak insulin levels by 45% and caused a rise in peak glucose levels from 7.1 +/- 0.6 to 9.0 +/- 0.9 mmol/l (p < 0.05). Diazoxide 0-3 insulin Homo sapiens 24-31 15811140-9 2005 DZX 100 mg reduced the peak insulin levels and insulin area under the curve by +/-20% (p < 0.05) but did not affect fasting or postprandial glucose levels. Diazoxide 0-3 insulin Homo sapiens 28-35 15811140-9 2005 DZX 100 mg reduced the peak insulin levels and insulin area under the curve by +/-20% (p < 0.05) but did not affect fasting or postprandial glucose levels. Diazoxide 0-3 insulin Homo sapiens 47-54 15811140-10 2005 The relatively limited insulin-suppressive effects in obese subjects were attributed to the low plasma DZX levels that were achieved in this group. Diazoxide 103-106 insulin Homo sapiens 23-30 15811140-14 2005 CONCLUSION: DZX-mediated insulin suppression is dose dependent in normal and in obese men. Diazoxide 12-15 insulin Homo sapiens 25-32 15734853-4 2005 This reduction of the decrement in intraislet insulin during induction of hypoglycemia caused an approximately 50% reduction (P = 0.0010) of the increase in plasma glucagon in the diazoxide clamps (from 29 +/- 3 to 35 +/- 2 pmol/l [102 +/- 9 to 123 +/- 8 pg/ml]) compared with the placebo clamps (from 28 +/- 2 to 43 +/- 5 pmol/l [98 +/- 7 to 151 +/- 16 pg/ml]). Diazoxide 180-189 insulin Homo sapiens 46-53 15339745-3 2005 After oral diazoxide, plasma insulin appeared to decline, as did C-peptide, again associated with dose-related increments in plasma glucose (P < 0.0001) and serum nonesterified fatty acids (P = 0.0141). Diazoxide 11-20 insulin Homo sapiens 29-36 16356235-5 2005 However, these antidotal approaches are associated with several shortcomings, including further exacerbation of insulin release by glucose and glucagon, leading only to a temporary beneficial effect and later relapse into hypoglycaemia, as well as the adverse effects of both glucagon and diazoxide. Diazoxide 289-298 insulin Homo sapiens 112-119 12213059-4 2002 6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (54) was found to bind and activate the SUR1/Kir6.2 K(ATP) channels in the low nanomolar range and to be at least 1000 times more potent than the reference compound diazoxide with respect to inhibition of insulin release from rat islets. Diazoxide 249-258 insulin Homo sapiens 289-296 15333483-3 2004 RESULTS: Diazoxide decreased circulating C-peptide concentrations by approximately 50%. Diazoxide 9-18 insulin Homo sapiens 41-50 15333483-5 2004 Meal-stimulated C-peptide concentration was significantly higher at 12 months (0.43 +/- 0.22 vs. 0.31 +/- 0.26 nmol/l, P = 0.018) and tended to fall less from clinical onset to 24 months in the diazoxide- vs. placebo-treated patients (-0.05 +/- 0.24 vs. -0.18 +/- 0.26 nmol/l, P = 0.064). Diazoxide 194-203 insulin Homo sapiens 16-25 15220194-3 2004 Treatment of type 1 and type 2 diabetic patients with the potassium channel opener diazoxide partially restores insulin secretion. Diazoxide 83-92 insulin Homo sapiens 112-119 12865318-0 2003 Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Diazoxide 0-9 insulin Homo sapiens 60-67 12865318-7 2003 Addition of diazoxide to islets cultured with 11 mM glucose decreased insulin secretion during static incubation, leading to relative preservation of insulin stores and enhanced insulin secretion during subsequent perifusion; FPIR increased by 162% (P < 0.05) and insulin pulse mass by 150% (P < 0.05) vs. no diazoxide. Diazoxide 12-21 insulin Homo sapiens 70-77 12865318-7 2003 Addition of diazoxide to islets cultured with 11 mM glucose decreased insulin secretion during static incubation, leading to relative preservation of insulin stores and enhanced insulin secretion during subsequent perifusion; FPIR increased by 162% (P < 0.05) and insulin pulse mass by 150% (P < 0.05) vs. no diazoxide. Diazoxide 12-21 insulin Homo sapiens 150-157 12865318-7 2003 Addition of diazoxide to islets cultured with 11 mM glucose decreased insulin secretion during static incubation, leading to relative preservation of insulin stores and enhanced insulin secretion during subsequent perifusion; FPIR increased by 162% (P < 0.05) and insulin pulse mass by 150% (P < 0.05) vs. no diazoxide. Diazoxide 12-21 insulin Homo sapiens 150-157 12865318-10 2003 In conclusion, the pattern of defects of insulin secretion present in TTDM (impaired FPIR and pulsatile insulin secretion, increased PI/I ratio) can be recapitulated in human islets cultured with 11 mM glucose for 96 h. These defects can be at least partially offset by concurrent inhibition of insulin secretion by diazoxide, which also preserves insulin stores. Diazoxide 316-325 insulin Homo sapiens 41-48 12522324-10 2002 Previous treatment with diazoxide was associated with a moderate 1.9 +/- 0.6 fold rise in insulin response to intravenous glucose (p=0.04) and 1.6 +/- 0.4 fold increased glucose potentiation of arginine-induced insulin secretion (GPAIS) (p=0.04). Diazoxide 24-33 insulin Homo sapiens 90-97 14706058-8 2004 Corresponding effects on insulin were 66.2 +/- 41.7 pmol/l for diazoxide vs. -84.2 +/- 51.5 for placebo, P < 0.03. Diazoxide 63-72 insulin Homo sapiens 25-32 14706058-11 2004 CONCLUSIONS: Bedtime treatment with diazoxide in Type 2 diabetic subjects on bedtime insulin and metformin has no significant side-effects, does not increase bedtime insulin supplementation, tends to ameliorate beta-cell function but fails to improve metabolic control. Diazoxide 36-45 insulin Homo sapiens 85-92 14660022-4 2003 The effects of harmane and pinoline were dose-dependent (EC(50): 5 and 25 microM, respectively) and these agents also blocked the inhibitory effects of the potassium channel agonist, diazoxide, on glucose-induced insulin release. Diazoxide 183-192 insulin Homo sapiens 213-220 12958175-8 2003 Diazoxide (150 microM) completely inhibited glucose-stimulated insulin release. Diazoxide 0-9 insulin Homo sapiens 63-70 12958175-12 2003 Furthermore, glibenclamide (20 microM) also stimulated the release of insulin from fluorescently labeled secretion granules, and diazoxide (150 microM) blocked that stimulated release of insulin. Diazoxide 129-138 insulin Homo sapiens 187-194 12414839-2 2002 BPDZ 154, an analog of diazoxide, inhibited both glucose-induced insulin secretion from isolated perifused islets and the secretion of insulin induced by glucose and tolbutamide. Diazoxide 23-32 insulin Homo sapiens 65-72 11078450-9 2000 Coculture with diazoxide and 27 mmol/l glucose significantly (P < 0.05) restored postculture insulin responses to glucose and lowered basal [Ca2+]i and normalized glucose-induced oscillatory activity. Diazoxide 15-24 insulin Homo sapiens 96-103 11815454-4 2002 alpha-Ketoisocaproate (KIC) and 3-isobutylmethylxanthine (IBMX) could be used in place of glucose and forskolin, respectively, to trigger insulin release in the presence of diazoxide. Diazoxide 173-182 insulin Homo sapiens 138-145 11249067-5 2001 With high glucose, insulin release was markedly potentiated by forskolin, glucagon, glucagon-like peptide-1, and arginine and inhibited by somatostatin, the Ca2+ channel blocker nitrendipine, and the ATP-sensitive K+ channel opener diazoxide. Diazoxide 232-241 insulin Homo sapiens 19-26 10050013-11 1999 In islets depolarized with 30 mM K+ in the presence of the KATP channel opener diazoxide, NOS inhibition by 5 mM L-NAME still markedly potentiated carbachol-induced insulin release (although less so than in normal islets) and suppressed glucagon release. Diazoxide 79-88 insulin Homo sapiens 165-172 9724074-6 1998 The aim of this study was to investigate further the role of insulin in leptin secretion in patients with PCOS by treating them for 10 days with diazoxide, an insulin-reducing compound. Diazoxide 145-154 insulin Homo sapiens 61-68 9877233-8 1998 Further, in the presence of diazoxide, a potent K+ ATP-channel opener, plus a depolarizing concentration of K+ the NOS-inhibitor L-NAME still markedly potentiated carbachol-induced insulin release and inhibited glucagon release. Diazoxide 28-37 insulin Homo sapiens 181-188 9724074-13 1998 After the administration of diazoxide a reduction in sum insulin (262 +/- 147 vs 679 +/- 341 microU/ml. Diazoxide 28-37 insulin Homo sapiens 57-64 9724074-6 1998 The aim of this study was to investigate further the role of insulin in leptin secretion in patients with PCOS by treating them for 10 days with diazoxide, an insulin-reducing compound. Diazoxide 145-154 insulin Homo sapiens 159-166 9540027-7 1998 RESULTS: Diazoxide inhibited glucagon-stimulated C-peptide secretion (mean increment 0.08 nmol/l vs. 0.18 nmol/l, P < 0.05), whereas octreotide had no such effect. Diazoxide 9-18 insulin Homo sapiens 49-58 9727845-8 1998 Diazoxide-resistant hyperinsulinism is characterized by its severity with higher plasma insulin levels. Diazoxide 0-9 insulin Homo sapiens 25-32 9626118-3 1998 We previously demonstrated that administration of diazoxide (DZ), an inhibitor of insulin secretion, to obese hyperinsulinemic Zucker rats resulted in less weight gain, enhanced insulin sensitivity, and improved glucose tolerance. Diazoxide 50-59 insulin Homo sapiens 82-89 9626118-3 1998 We previously demonstrated that administration of diazoxide (DZ), an inhibitor of insulin secretion, to obese hyperinsulinemic Zucker rats resulted in less weight gain, enhanced insulin sensitivity, and improved glucose tolerance. Diazoxide 61-63 insulin Homo sapiens 82-89 9238070-2 1997 It is closed by glucose metabolism, which stimulates secretion, and opened by the drug diazoxide, which inhibits insulin release. Diazoxide 87-96 insulin Homo sapiens 113-120 9653515-2 1998 We found that glucose-induced insulin release was potentiated by L-NAME in the absence or presence of diazoxide, a potent K+ATP channel opener, as well as in the presence of diazoxide plus a depolarizing concentration of K+. Diazoxide 102-111 insulin Homo sapiens 30-37 9653515-2 1998 We found that glucose-induced insulin release was potentiated by L-NAME in the absence or presence of diazoxide, a potent K+ATP channel opener, as well as in the presence of diazoxide plus a depolarizing concentration of K+. Diazoxide 174-183 insulin Homo sapiens 30-37 9473513-1 1998 To investigate the possible involvement of some intracellular metabolic signaling other than the ATP derived from glucose metabolism under protein kinase A (PKA) activation, we measured the insulin secretory capacity stimulated by glucose and other fuel secretagogues using diazoxide-treated pancreatic islets. Diazoxide 274-283 insulin Homo sapiens 190-197 9144288-3 1997 They are also the target for clinically important drugs such as sulphonylureas, which stimulate secretion, and the K+ channel opener diazoxide, which inhibits insulin release. Diazoxide 133-142 insulin Homo sapiens 159-166 7852532-6 1995 Diazoxide administration worsened glucose tolerance in several subjects and reduced fasting and glucose-stimulated insulin levels by approximately 50% in both control and obese subjects. Diazoxide 0-9 insulin Homo sapiens 115-122 9160819-1 1997 In a previous study performed in adult obese and normal-weight male subjects, we found that suppression of insulin levels by diazoxide reduced testosterone and increased sex hormone-binding globulin (SHBG) blood concentrations. Diazoxide 125-134 insulin Homo sapiens 107-114 9224548-3 1997 Two K(+)-ATP channel openers (diazoxide and BPDZ44) inhibited; while a K(+)-ATP channel blocker (tolbutamide) and metabolizable sugars (glucose, glyceraldehyde) significantly stimulated the output of insulin. Diazoxide 30-39 insulin Homo sapiens 200-207 8826981-1 1996 Twenty islet cell antibody (ICA)-positive patients, aged 19-38 years, with IDDM were randomized at onset to treatment with either diazoxide, a K+ channel opener that inhibits the release of insulin, or placebo for 3 months, in addition to multiple insulin injection therapy. Diazoxide 130-139 insulin Homo sapiens 190-197 8710037-4 1996 Treatments aimed at decreasing endogenous insulin secretion by either dietary intervention alone or in combination with acarbose, octreotide or diazoxide had only limited success, while a 2-week course of immunosuppression with prednisone was without any antihypoglycaemic effect. Diazoxide 144-153 insulin Homo sapiens 42-49 7805953-4 1994 Recent studies suggest that these drugs and diazoxide can influence insulin secretion from electropermeabilized beta-cells in which K(+)-ATP channels and other plasma membrane ion channels are inoperative. Diazoxide 44-53 insulin Homo sapiens 68-75 8452640-0 1993 Interaction of diazoxide and cromakalim with ATP-regulated K+ channels in rodent and clonal insulin-secreting cells. Diazoxide 15-24 insulin Homo sapiens 92-99 8445035-6 1993 Insulin concentrations were 4-5 times greater with dextrose alone or in combination with diazoxide than with octreotide (P < 0.01). Diazoxide 89-98 insulin Homo sapiens 0-7 7810974-6 1994 By providing continuous data about intensity of glucose infusion and blood glucose, it helps to detect an occult secreting tumor (a preoperative therapeutic test with diazoxide requires stopping treatment for at least one month before surgery to avoid false negative results) and confirms the total ablation of abnormal insulin-producing cells. Diazoxide 167-176 insulin Homo sapiens 320-327 8344209-0 1993 Modification of insulin resistance by diazoxide in obese Zucker rats. Diazoxide 38-47 insulin Homo sapiens 16-23 8344209-4 1993 Diazoxide-treated obese and lean animals showed significantly lower postabsorptive plasma insulin concentrations (P < 0.005) than their respective obese and lean PF and C subgroups. Diazoxide 0-9 insulin Homo sapiens 90-97 8452640-3 1993 In the present study, a detailed investigation of interactions of diazoxide and another K+ channel opener, cromakalim, with K+ATP channels has been performed in individual insulin-secreting cells using patch-clamp techniques. Diazoxide 66-75 insulin Homo sapiens 172-179 8420818-7 1993 Administering an inhibitor of insulin release, diazoxide, to hyperglycemic rats blocked the fall in pancreatic insulin content and prevented the rise in the percentage of proinsulin. Diazoxide 47-56 insulin Homo sapiens 171-181 8157092-4 1993 The index of insulin sensitivity was significantly decreased in pretreated "responders" as compared to healthy persons (19 +/- 3 vs 39 +/- 6 and 20 +/- 3 vs 37 +/- 5 mumol.kg-1.min-1 per mU.l-1 x 100, p < 0.01) and it was improved during diazoxide administration (27 +/- 4 vs 19 +/- 3 and 35 +/- 12 vs 20 +/- 3 mumol.kg-1.min-1 per mU.l-1 x 100, p < 0.05). Diazoxide 241-250 insulin Homo sapiens 13-20 8420818-7 1993 Administering an inhibitor of insulin release, diazoxide, to hyperglycemic rats blocked the fall in pancreatic insulin content and prevented the rise in the percentage of proinsulin. Diazoxide 47-56 insulin Homo sapiens 30-37 8157092-5 1993 Significantly decreased insulin sensitivity in pretreated "non-responders" (25 +/- 5 vs 39 +/- 6 and 28 +/- 6 vs 37 +/- 5 mumol.kg-1.min-1 per mU.l-1 x 100, p < 0.05) was not improved by diazoxide administration. Diazoxide 190-199 insulin Homo sapiens 24-31 1521732-6 1992 Diazoxide on the other hand reduced the rate of the 64 kDa/glutamic acid decarboxylase autoantigen synthesis in parallel with an inhibition of glucose-stimulated insulin release. Diazoxide 0-9 insulin Homo sapiens 162-169 1447492-9 1992 A decrease of immunoreactive insulin levels in other patient with insulinoma and an increase in plasma glucose to the euglycemic range during two months allowed a reduction of doses of somatostatin analogue and diazoxide. Diazoxide 211-220 insulin Homo sapiens 29-36 1379358-2 1992 This paper reports 16 months of palliative treatment with cyproheptadine and diazoxide in a child with hyperinsulinism initially diagnosed at 6 months of age (her insulin level was 80 microU/mL while her glucose level was 38 mg/dL). Diazoxide 77-86 insulin Homo sapiens 108-115 2498378-0 1989 Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. Diazoxide 32-41 insulin Homo sapiens 21-28 1898744-5 1991 While continuing leuprolide treatment, the women were administered oral diazoxide (300 mg/day) for 10 days to suppress serum insulin levels. Diazoxide 72-81 insulin Homo sapiens 125-132 1898744-6 1991 Diazoxide treatment resulted in suppressed insulin release during a 100-g oral glucose tolerance test (insulin area under the curve, 262 +/- 55 nmol/min.L on day 0 vs. 102 +/- 33 nmol/min.L on day 10; P less than 0.05) and deterioration of glucose tolerance. Diazoxide 0-9 insulin Homo sapiens 43-50 1898744-6 1991 Diazoxide treatment resulted in suppressed insulin release during a 100-g oral glucose tolerance test (insulin area under the curve, 262 +/- 55 nmol/min.L on day 0 vs. 102 +/- 33 nmol/min.L on day 10; P less than 0.05) and deterioration of glucose tolerance. Diazoxide 0-9 insulin Homo sapiens 103-110 2220936-1 1990 Suppression of serum insulin levels with diazoxide is associated with a decrease in serum testosterone and an increase in serum sex hormone-binding globulin in obese women with the polycystic ovary syndrome. Diazoxide 41-50 insulin Homo sapiens 21-28 2220936-3 1990 Insulin release in response to 100 gm oral glucose administration decreased from 108.0 +/- 28.2 to 49.3 +/- 5.2 nmol.min/L (p = 0.05) after diazoxide administration. Diazoxide 140-149 insulin Homo sapiens 0-7 2684032-7 1989 A diazoxide toxicity index was obtained by multiplying the dose of diazoxide by the insulin:glucose ratio to relate the diazoxide dose to the severity of the disease. Diazoxide 2-11 insulin Homo sapiens 84-91 2220936-0 1990 Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women. Diazoxide 38-47 insulin Homo sapiens 21-28 2504288-1 1989 Drugs which influence the electrical activity of insulin-secreting B cells of mammalian islets of Langerhans by closing (tolbutamide and glibenclamide) or opening (diazoxide) ATP-sensitive potassium channels were applied to the ventricular muscle of the rat. Diazoxide 164-173 insulin Homo sapiens 49-56 2498378-1 1989 To test the hypothesis that insulin plays a role in the hyperandrogenism of obese women with polycystic ovary syndrome, we conducted a prospective study in which the androgen status of five obese women with polycystic ovary syndrome was assessed on two occasions: before and after 10 days of oral diazoxide (100 mg, three times daily) administration. Diazoxide 297-306 insulin Homo sapiens 28-35 2542036-4 1989 The administration of diazoxide (Proglicem1) for three days (3 mg.kg-1 per day) caused a fall in serum insulin concentrations, together with an increase in the metabolic clearance rate of insulin and increased tissue sensitivity to insulin. Diazoxide 22-31 insulin Homo sapiens 103-110 2542036-4 1989 The administration of diazoxide (Proglicem1) for three days (3 mg.kg-1 per day) caused a fall in serum insulin concentrations, together with an increase in the metabolic clearance rate of insulin and increased tissue sensitivity to insulin. Diazoxide 22-31 insulin Homo sapiens 188-195 2542036-4 1989 The administration of diazoxide (Proglicem1) for three days (3 mg.kg-1 per day) caused a fall in serum insulin concentrations, together with an increase in the metabolic clearance rate of insulin and increased tissue sensitivity to insulin. Diazoxide 22-31 insulin Homo sapiens 188-195 6358071-4 1983 Diazoxide treatment resulted in a significant suppression of glucose-stimulated early (insulin area 0-30 min) (P less than 0.05), late (insulin area 30-120 min) (P less than 0.01) and total insulin response (insulin area 0-120 min) (P less than 0.01) as well as a mild deterioration of glucose tolerance. Diazoxide 0-9 insulin Homo sapiens 87-94 3314727-5 1987 Diazoxide given to one baby suppressed previously "normal" insulin concentrations still further (4.2 to less than 1.6 microU/ml) and thereby restored the hepatic glucose production rate to normal. Diazoxide 0-9 insulin Homo sapiens 59-66 3949281-0 1986 Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes. Diazoxide 39-48 insulin Homo sapiens 14-21 3949281-1 1986 Insulin binding to monocytes and the counterregulatory hormone response to intravenous insulin was determined in six normal subjects and eight patients with non-insulin dependent diabetes mellitus (NIDDM), before and after seven days treatment with oral diazoxide. Diazoxide 254-263 insulin Homo sapiens 0-7 3949281-4 1986 Diazoxide appears to cause post-receptor insulin resistance in NIDDM, and it may be a useful tool for studying post-receptor binding events. Diazoxide 0-9 insulin Homo sapiens 41-48 6311653-4 1983 In contrast, tumors of group B are characterized by scarce well-granulated typical B-cells, a medullary-type histologic structure, and irregular insulin immunofluorescence; functionally these tumors show elevated circulating levels of proinsulin-like component and a marked resistance of insulin secretion to somatostatin and diazoxide inhibition. Diazoxide 326-335 insulin Homo sapiens 235-245 2447283-0 1987 Interaction of diazoxide, tolbutamide and ATP4- on nucleotide-dependent K+ channels in an insulin-secreting cell line. Diazoxide 15-24 insulin Homo sapiens 90-97 6308035-2 1983 The enzyme in the insulinomas, but not that in the nearby pancreases, was inhibited by diazoxide, which is a known inhibitor of insulin secretion in vitro and in vivo. Diazoxide 87-96 insulin Homo sapiens 18-25 6358071-4 1983 Diazoxide treatment resulted in a significant suppression of glucose-stimulated early (insulin area 0-30 min) (P less than 0.05), late (insulin area 30-120 min) (P less than 0.01) and total insulin response (insulin area 0-120 min) (P less than 0.01) as well as a mild deterioration of glucose tolerance. Diazoxide 0-9 insulin Homo sapiens 136-143 6358071-4 1983 Diazoxide treatment resulted in a significant suppression of glucose-stimulated early (insulin area 0-30 min) (P less than 0.05), late (insulin area 30-120 min) (P less than 0.01) and total insulin response (insulin area 0-120 min) (P less than 0.01) as well as a mild deterioration of glucose tolerance. Diazoxide 0-9 insulin Homo sapiens 136-143 6358071-4 1983 Diazoxide treatment resulted in a significant suppression of glucose-stimulated early (insulin area 0-30 min) (P less than 0.05), late (insulin area 30-120 min) (P less than 0.01) and total insulin response (insulin area 0-120 min) (P less than 0.01) as well as a mild deterioration of glucose tolerance. Diazoxide 0-9 insulin Homo sapiens 136-143 6358071-6 1983 Similarly, there was a marked increase of the antilipolytic effect of insulin after short-term treatment with diazoxide (P less than 0.05). Diazoxide 110-119 insulin Homo sapiens 70-77 7029441-7 1981 Furthermore, Diazoxide therapy in two patients caused a mild but consistent decrease in the number of insulin receptor sites, and the institution of continuous nocturnal nasogastric feedings in a patient with glycogen storage disease type I was followed by amelioration of the hypoglycemia and a marked increase in 125I-insulin specific binding from 5.2 to 9.5%. Diazoxide 13-22 insulin Homo sapiens 102-109 6759356-1 1982 Insulin binding to monocytes was assessed before and after plasma insulin suppression by diazoxide in 14 obesity-related diabetic subjects. Diazoxide 89-98 insulin Homo sapiens 0-7 6759356-1 1982 Insulin binding to monocytes was assessed before and after plasma insulin suppression by diazoxide in 14 obesity-related diabetic subjects. Diazoxide 89-98 insulin Homo sapiens 66-73 6759356-3 1982 Despite an increase in insulin binding after 7 days of diazoxide therapy, no improvement in carbohydrate tolerance could be demonstrated. Diazoxide 55-64 insulin Homo sapiens 23-30 6303933-7 1983 In our experience, insulin response to diazoxide infusion in patients with insulinoma may provide additional information for diagnosis. Diazoxide 39-48 insulin Homo sapiens 19-26 6264722-6 1981 After 7 days of diazoxide treatment, a further reduction of glucose infusion (5.8 g/h), together with a lowering of plasma insulin levels (7-18 microunits/ml) was observed. Diazoxide 16-25 insulin Homo sapiens 123-130 6264722-7 1981 Both in the basal state and during diazoxide treatment a circadian pattern of glucose requirement was noted, with lower glucose need and plasma insulin levels during the night. Diazoxide 35-44 insulin Homo sapiens 144-151 218752-4 1979 Administration of diazoxide led to a substantial fall in serum insulin levels, accompanied by reduction in VLDL production and in serum triglyceride concentration. Diazoxide 18-27 insulin Homo sapiens 63-70 7017987-6 1981 After diazoxide, insulin levels fell to 25.0 +/- 6.2 microU/ml and 25.0 +/- 6.6 microU/ml, respectively. Diazoxide 6-15 insulin Homo sapiens 17-24 216887-4 1979 Infusion of diazoxide (600 mg) with calcium blocked the stimulation of the latter on insulin secretion. Diazoxide 12-21 insulin Homo sapiens 85-92 4946718-0 1969 [Antagonistic action of intestinal hormones and diazoxide on insulin secretion in humans]. Diazoxide 48-57 insulin Homo sapiens 61-68 358739-0 1978 Paradoxical enhancement of tolbutamide-induced insulin release by diazoxide in a patient with islet cell hyperplasia. Diazoxide 66-75 insulin Homo sapiens 47-54 358739-4 1978 Diazoxide potentiated the tolbutamide-induced insulin response, and this effect of diazoxide was not blocked by propranolol. Diazoxide 0-9 insulin Homo sapiens 46-53 358739-5 1978 In the diagnostic work up of islet cell hyperplasia, dizoxide may paradoxically potentiate tolbutamide-induced insulin release, a finding which may falsely suggest progression of the disease. Diazoxide 53-61 insulin Homo sapiens 111-118 343476-6 1977 The serum glucose level was significant higher (P less than 0.01), the serum insulin level was significant lower (P less than 0.01) when induction of paralysis was attempted under diazoxide cover than during the untreated stimulation phase. Diazoxide 180-189 insulin Homo sapiens 77-84 930951-6 1977 The administration of diazoxide was effective in our patient, substantially reducing the plasma insulin level; this agent may be the "insulin-antagonist" of choice for use in sulfonylurea-induced hypoglycemia. Diazoxide 22-31 insulin Homo sapiens 96-103 930951-6 1977 The administration of diazoxide was effective in our patient, substantially reducing the plasma insulin level; this agent may be the "insulin-antagonist" of choice for use in sulfonylurea-induced hypoglycemia. Diazoxide 22-31 insulin Homo sapiens 134-141 5028220-0 1972 The use of diazoxide inhibition of insulin secretion as a tool to investigate insulin stimulation by other agents. Diazoxide 11-20 insulin Homo sapiens 35-42 5028220-0 1972 The use of diazoxide inhibition of insulin secretion as a tool to investigate insulin stimulation by other agents. Diazoxide 11-20 insulin Homo sapiens 78-85 4330005-7 1971 Three islet-cell tumor patients with less than 46% proinsulin-like component had favorable therapeutic responses to diazoxide whereas one patient with over 80% proinsulin-like component was completely refractory. Diazoxide 116-125 insulin Homo sapiens 51-61 5761863-0 1969 Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man. Diazoxide 75-84 insulin Homo sapiens 32-39 437366-2 1979 Insulin"s suppression by diazoxide in these 10 subjects resulted in a mild glucose intolerance and an increase in insulin"s receptors in seven of the 10 subjects. Diazoxide 25-34 insulin Homo sapiens 0-7 437366-2 1979 Insulin"s suppression by diazoxide in these 10 subjects resulted in a mild glucose intolerance and an increase in insulin"s receptors in seven of the 10 subjects. Diazoxide 25-34 insulin Homo sapiens 114-121 178856-14 1976 Diazoxide, a potent insulin inhibitor in vivo, demonstrates a similar activity in vitro. Diazoxide 0-9 insulin Homo sapiens 20-27 55717-4 1976 It is likely that the observed improvements reflected increased insulin stores which resulted from diazoxide inhibition of insulin release. Diazoxide 99-108 insulin Homo sapiens 64-71 55717-4 1976 It is likely that the observed improvements reflected increased insulin stores which resulted from diazoxide inhibition of insulin release. Diazoxide 99-108 insulin Homo sapiens 123-130 55717-6 1976 Pharmacological agents such as diazoxide, which inhibit glucose-induced insulin release, may have a place in preserving and restoring insulin secretion in diabetes. Diazoxide 31-40 insulin Homo sapiens 72-79 4558084-0 1972 Comparison of the inhibitory effects of diphenylhydantoin and diazoxide upon insulin secretion from the isolated perfused pancreas. Diazoxide 62-71 insulin Homo sapiens 77-84 4317299-0 1970 Enhancement of insulin release to acute glycaemic stimulation with depression of basal insulin production rates in insulinoma following diazoxide administration. Diazoxide 136-145 insulin Homo sapiens 15-22 4902707-2 1966 Inhibition of glucose induced insulin release by diazoxide]. Diazoxide 49-58 insulin Homo sapiens 30-37 4334867-0 1969 The morphological substrate of the inhibition of insulin secretion by diazoxide. Diazoxide 70-79 insulin Homo sapiens 49-56 4299219-0 1968 Further studies on diazoxide suppression of insulin release from abnormal and normal islet tissue in man. Diazoxide 19-28 insulin Homo sapiens 44-51 4299220-0 1968 Inhibition of insulin release by diazoxide and its relation to catecholamine effects in man. Diazoxide 33-42 insulin Homo sapiens 14-21 4875709-0 1968 The action of diazoxide on insulin secretion, medullo-adrenal secretion, and the liberation of catecholamines. Diazoxide 14-23 insulin Homo sapiens 27-34 4957238-0 1966 [Demonstration of the direct inhibitory action of diazoxide on insulin secretion by the pancreas]. Diazoxide 50-59 insulin Homo sapiens 63-70 4961590-0 1966 [Biological and immunological determinations of insulin demonstrating that diazoxide checks insulin secretion]. Diazoxide 75-84 insulin Homo sapiens 48-55 4961590-0 1966 [Biological and immunological determinations of insulin demonstrating that diazoxide checks insulin secretion]. Diazoxide 75-84 insulin Homo sapiens 92-99 4158956-0 1966 Effects of diazoxide on insulin secretion in vitro. Diazoxide 11-20 insulin Homo sapiens 24-31 4223085-0 1966 Effects of diazoxide administration on plasma glucose, insulin, and lipids in Von Gierke"s disease. Diazoxide 11-20 insulin Homo sapiens 55-62 34046157-3 2021 Diazoxide is first-line therapy for neonatal hypoglycemia and works by inhibiting insulin secretion. Diazoxide 0-9 insulin Homo sapiens 82-89 4222908-0 1966 [Diazoxide experimentally exercises an inhibitory action on the basal secretion of insulin]. Diazoxide 1-10 insulin Homo sapiens 83-90 4223206-0 1966 [Participation of insulin in diazoxide hyperglycemia]. Diazoxide 29-38 insulin Homo sapiens 18-25 18476985-0 2008 Weight loss in obese men by caloric restriction and high-dose diazoxide-mediated insulin suppression. Diazoxide 62-71 insulin Homo sapiens 81-88 34055813-1 2020 We present the case of an infant referred to our NICU born at 39 weeks" gestation with persistent hypoglycemia with elevated insulin levels (HI) requiring diazoxide to maintain normoglycemia. Diazoxide 155-164 insulin Homo sapiens 125-132 32274651-3 2020 Diazoxide was originally approved as an anti-hypertensive medication, but also is known to bind ATP-sensitive K channels in the beta cells of the pancreas, ultimately leading to inhibition of insulin release. Diazoxide 0-9 insulin Homo sapiens 192-199 31218401-7 2019 Fifty-two percent of patients were diazoxide-unresponsive with significantly shorter fasting tolerance time and higher serum insulin level compared with the responsive patients. Diazoxide 35-44 insulin Homo sapiens 125-132 29618011-0 2018 Effects of Diazoxide-Mediated Insulin Suppression on Glucose and Lipid Metabolism in Nondiabetic Obese Men. Diazoxide 11-20 insulin Homo sapiens 30-37 29618011-1 2018 Context: It has been suggested that stimulation of lipolysis by diazoxide (DZX)-mediated insulin suppression may be useful in treating obesity. Diazoxide 64-73 insulin Homo sapiens 89-96 29618011-1 2018 Context: It has been suggested that stimulation of lipolysis by diazoxide (DZX)-mediated insulin suppression may be useful in treating obesity. Diazoxide 75-78 insulin Homo sapiens 89-96 29618011-7 2018 After dose reduction to a level free of clinical side effects, DZX treatment was associated with a markedly greater decrease in fasting insulin levels than PL (-72.3 +- 3.5% vs -23.0 +- 12.6%; P < 0.001) and a significant improvement of blood pressure and plasma lipid levels. Diazoxide 63-66 insulin Homo sapiens 136-143 28507564-10 2017 Medical management in patients with insulinoma include diazoxide which suppresses insulin release. Diazoxide 55-64 insulin Homo sapiens 36-43 28115493-8 2017 Diazoxide, verapamil and Ca2+ omission inhibited insulin secretion induced by the esculentin-2CHa(1-30) analogues suggesting an action on KATP and Ca2+ channels also. Diazoxide 0-9 insulin Homo sapiens 49-56 27603903-11 2016 No statistically significant differences were observed between the groups concerning the change in absolute weight or glycosylated hemoglobin after 2 months, but the plasma glucose concentrations (basal and after OGTT) were significantly greater in the patients receiving DZX treatment vs those receiving the placebo, whereas the plasma increases in insulin after OGTT were lower. Diazoxide 272-275 insulin Homo sapiens 350-357 26137438-4 2015 METHODS: Circulating insulin levels were reduced by about 50% in diet-induced and genetically obese mice by treatments with diazoxide or streptozotocin, respectively. Diazoxide 124-133 insulin Homo sapiens 21-28 26137438-9 2015 Moreover, responsiveness of blood glucose levels to injected insulin was improved by streptozotocin and diazoxide treatments of obese mice without changes in body weight. Diazoxide 104-113 insulin Homo sapiens 61-68 21378174-1 2011 OBJECTIVE: We tested the hypotheses that in nondiabetic individuals, partial inhibition of insulin secretion with the ATP-sensitive K(+) channel agonist (opener) diazoxide, compared with placebo, results in higher plasma glucose and higher plasma glucagon concentrations after a mixed meal and after administration of the sulfonylurea glimepiride. Diazoxide 162-171 insulin Homo sapiens 91-98 21378174-3 2011 RESULTS: With diazoxide administration, insulin (P = 0.0016) and C-peptide (P = 0.0287) concentrations were decreased and glucose concentrations were increased (e.g., 180-min values of 106 +- 4 mg/dL [5.9 +- 0.2 mmol/L] compared with 87 +- 2 mg/dL [4.8 +- 0.1 mmol/L] with placebo; P < 0.0001), but glucagon concentrations were no different after the mixed meal. Diazoxide 14-23 insulin Homo sapiens 40-47 20028939-1 2010 OBJECTIVE Continuous beta-cell rest with diazoxide preserves residual endogenous insulin production in type 1 diabetes. Diazoxide 41-50 insulin Homo sapiens 81-88 20028939-3 2010 In a double-blind study, we tested whether lower, intermittent dosing of diazoxide had beneficial effects on insulin production, metabolic control, and autoimmunity markers in the absence of side effects. Diazoxide 73-82 insulin Homo sapiens 109-116 19218500-3 2009 Diazoxide (DZ) was used to decrease serum insulin and generate hyperglycemia. Diazoxide 0-9 insulin Homo sapiens 42-49 19218500-3 2009 Diazoxide (DZ) was used to decrease serum insulin and generate hyperglycemia. Diazoxide 11-13 insulin Homo sapiens 42-49 28400489-0 2017 Diazoxide for Lowering Insulin Levels in Breast Cancer Patients. Diazoxide 0-9 insulin Homo sapiens 23-30 26878387-5 2016 Although lowering of insulin levels with diet or drugs such as metformin and diazoxide seems generally beneficial, some practitioners also utilize strategic elevations of insulin levels in combination with chemotherapeutic drugs. Diazoxide 77-86 insulin Homo sapiens 21-28 26878387-7 2016 With a specific focus on dietary restriction, insulin administration and the insulin-lowering drug diazoxide, such modifications of the insulin/IGF-1 system are the topic of this review. Diazoxide 99-108 insulin Homo sapiens 77-84 26878387-7 2016 With a specific focus on dietary restriction, insulin administration and the insulin-lowering drug diazoxide, such modifications of the insulin/IGF-1 system are the topic of this review. Diazoxide 99-108 insulin Homo sapiens 77-84 26392140-4 2015 Diazoxide blocks insulin release from the pancreas by opening the SUR1/Kir6.2 channels in ss-cells. Diazoxide 0-9 insulin Homo sapiens 17-24 26116696-5 2015 Group B (three patients with fasting hypoglycemic episodes) was mainly characterized by large insulin responses to 1 mmol/L glucose, resulting in very high basal secretion rates that were inhibited by diazoxide and restored by tolbutamide but were not further augmented by other agents except for high levels of CaCl2. Diazoxide 201-210 insulin Homo sapiens 94-101 23303986-1 2012 INTRODUCTION: We conducted a pilot project to test the hypothesis that decreasing insulin concentrations with diazoxide would affect parameters of vitamin D in obese women with and without polycystic ovary syndrome (PCOS). Diazoxide 110-119 insulin Homo sapiens 82-89 19623043-8 2009 Insulin secretion was blocked with diazoxide (2.5-30 mg/kg/day). Diazoxide 35-44 insulin Homo sapiens 0-7 18476985-1 2008 OBJECTIVE: To examine the concept whether high-dose diazoxide (DZX)-mediated insulin suppression, in combination with moderate caloric restriction and increased physical activity, can establish a weight loss of at least 15% in obese hyperinsulinaemic men. Diazoxide 52-61 insulin Homo sapiens 77-84 18476985-1 2008 OBJECTIVE: To examine the concept whether high-dose diazoxide (DZX)-mediated insulin suppression, in combination with moderate caloric restriction and increased physical activity, can establish a weight loss of at least 15% in obese hyperinsulinaemic men. Diazoxide 63-66 insulin Homo sapiens 77-84 18476985-14 2008 CONCLUSION: High-dose DZX-mediated insulin suppression, in combination with moderate caloric restriction and lifestyle advice, is associated with a clinically relevant degree of weight reduction. Diazoxide 22-25 insulin Homo sapiens 35-42